-Merck (NYSE: MRK), known as MSD outside the United States and Canada, has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited &ldquo...
Profluent, a leader in frontier AI for protein design, announced a $106 million financing co-led by Altimeter Capital and Bezos Expeditions, with p...
Synthio Labs, a clinical-grade voice AI company transforming how life sciences organisations engage clinicians and patients, announced that it has raised...
Halda to be acquired by Johnson & Johnson for $3.05 billion in cash Halda recently presented positive Phase 1/2 data for HLD-0915 in metastatic ca...
Third Rock Ventures and Parse Biosciences announced a strategic collaboration to create an unprecedented atlas of 5 million T cell receptors (TCRs)...
Each shareholder is estimated to receive US$1.82 per share plus one CVR per common share - - Transaction expected to close in the first quarter of 20...
Launched its first Asia office to support biotech and healthtech innovation and collaboration within the region The Asia office will house the Angelin...
Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet fut...
SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collab...
Reinvestment from existing backers underscores confidence in Elephas' predictive approach to improving immunotherapy treatment response rates Elephas B...
Santhera Pharmaceuticals (SIX: SANN) announces the closing of a USD 13 million royalty monetization agreement, first announced in September 2025, t...
Expected to be immediately accretive to Adjusted Earnings Per Share (EPS)¹ after close Attractive return profile given high growth and strong margi...
Co-led by Forbion and Sofinnova Partners, along with founding investor Monograph Capital, and Weatherden Innovative lead program, ELV001, in-licensed ...
Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have ...
© 2026 Biopharma Boardroom. All Rights Reserved.
